Valbiotis: Invest Securities reduces its target

(CercleFinance.com) - Invest Securities maintains its buy rating on Valbiotis shares, with a price target lowered from €5 to €3, notably due to poor visibility on the outlook.


The analyst reports that the half-year results came as no surprise, with cash at the end of June of €18.5m in line with expectations.

In addition, the Group has decided to adapt its organization to offer greater agility. This business plan, which will be detailed in Q1 25, involves focusing on growth and closing the Riom preclinical platform.

This closure will generate cost savings of 2.2mE/year, which we are integrating. At the same time, we are lowering our sales assumptions in order to align ourselves with the company's cash visibility, evaluated at current 2026, which is the most viable assumption on which to base our decision at this stage", says the broker, who now awaits detailed communication of the plan in Q1 25.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.